Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand.

Application of research-grade diagnostic kits in clinical drug development has grown commensurate with the increased interest in utilization of biomarkers as drug development tools. Since novel biomarkers are frequently macromolecular, immunoassay methodology comprises the 'technology-of-choice' for biomarker quantification. In particular, commercial research-grade immunoassay kits are appealing for use in biomarker quantification during clinical phase drug development because of their ready availability, ease of operation and perceived convenience. However, bioanalytical validation issues arise often during the application of commercial kits, as GLP regulatory-compliant application places greater demands on kit design and performance. In this review, we have used the receptor activator of nuclear factor kappaB ligand (RANKL) as a model system to offer some insights into the challenges that can be encountered in the application of 'research-grade' diagnostic kits in support of clinical drug development. Currently only a few assays are available commercially for the determination of circulating concentrations of sRANKL. Of these, two immunoassay designs have been most often. The first design employs human osteoprotegerin to capture unbound sRANKL from serum and, thereby, provides a measure of circulating free concentrations. In contrast, the other common assay design first involves preincubation of serum samples with human osteoprotegerin to convert the free fraction of sRANKL to the osteoprotegerin-bound complex. The bound fraction is subsequently captured by an anti-osteoprotegerin antibody. In both immunoassay designs, detection is accomplished with an anti-sRANKL enzyme conjugation system. In this report we review these sRANKL immunoassay designs critically from the perspective of their potential suitability as drug development biomarker tools. In addition, analytical challenges relevant to the application of these 'research-grade' diagnostic kits for regulatory-compliant determination of sRANKL concentrations are discussed.

[1]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  N. Maalouf,et al.  The Role of Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications , 2007 .

[3]  J. Aubin,et al.  Osteoprotegerin and its Ligand: A New Paradigm for Regulation of Osteoclastogenesis and Bone Resorption , 2000, Osteoporosis International.

[4]  D. Heymann,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.

[5]  P. Pietschmann,et al.  Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. , 2008, Current medicinal chemistry.

[6]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[7]  W. Dougall,et al.  RANK ligand as a therapeutic target for bone metastases and multiple myeloma. , 2008, Cancer treatment reviews.

[8]  Barbara Kruk,et al.  Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. , 2005, Archivum immunologiae et therapiae experimentalis.

[9]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[10]  J. Wagner,et al.  Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.

[11]  M. Muñoz-Torres,et al.  The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women , 2005, Osteoporosis International.

[12]  M. Walsh,et al.  Biology of the TRANCE axis. , 2003, Cytokine & growth factor reviews.

[13]  N. Lane,et al.  Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). , 2004, The Journal of clinical endocrinology and metabolism.

[14]  G. Roodman.  Treatment strategies for bone disease , 2007, Bone Marrow Transplantation.

[15]  A. Angeli,et al.  Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? , 2005, Journal of endocrinological investigation.

[16]  R. Eastell,et al.  Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. , 2005, The Journal of clinical endocrinology and metabolism.

[17]  L. Hofbauer,et al.  Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women , 2004, Clinical endocrinology.

[18]  P. Bernabei,et al.  Risedronate Reduces Osteoclast Precursors and Cytokine Production in Postmenopausal Osteoporotic Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  P. Kostenuik,et al.  Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. , 2005, Bone.

[20]  Qingbo Xu,et al.  Soluble RANKL and risk of nontraumatic fracture. , 2004, JAMA.

[21]  K. Hirokawa,et al.  Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus. , 2001, Endocrinology.

[22]  E. Schwarz,et al.  Increased lymphangiogenesis in joints of mice with inflammatory arthritis , 2007, Arthritis research & therapy.

[23]  Brendan F Boyce,et al.  Biology of RANK, RANKL, and osteoprotegerin , 2007, Arthritis research & therapy.

[24]  M. Milla,et al.  Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand* , 2005, Journal of Biological Chemistry.

[25]  W. Colburn,et al.  Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing , 2003, Journal of clinical pharmacology.

[26]  Qingbo Xu,et al.  Soluble Receptor Activator of Nuclear Factor-&kgr;B Ligand and Risk for Cardiovascular Disease , 2007, Circulation.

[27]  Thomas Layloff,et al.  Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies , 1992, Pharmaceutical Research.

[28]  M. Brandi,et al.  Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? , 2004, The Journal of rheumatology.

[29]  John A. Wagner,et al.  A cost-effectiveness approach to the qualification and acceptance of biomarkers , 2006, Nature Reviews Drug Discovery.

[30]  E. Kobyliansky,et al.  Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population. , 2004, European journal of endocrinology.

[31]  W. Maśliński,et al.  High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. , 2002, Arthritis and rheumatism.

[32]  J. W. Findlay,et al.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. , 2000, Journal of pharmaceutical and biomedical analysis.

[33]  W. Woloszczuk,et al.  Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum. , 2003, Clinical laboratory.

[34]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[35]  Wendell C. Smith,et al.  Validation of Assays for the Bioanalysis of Novel Biomarkers: Practical Recommendations for Clinical Investigation of New Drug Entities , 2003 .

[36]  N. Baldini,et al.  Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis. , 2006, The Journal of bone and joint surgery. American volume.

[37]  Stanley B. Cohen,et al.  Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases. , 2006, Arthritis and rheumatism.

[38]  J. Marc,et al.  Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.